A systematic review of biomarkers associated with RA concluded that a substandard response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for RA was indicated with CRP levels >7.1 mg/L85. This evidence concerns the gene CRP and rheumatoid arthritis.